{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:17:34Z","timestamp":1767388654464,"version":"3.48.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104988","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T14:44:16Z","timestamp":1761403456000},"page":"104988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Gamma Knife radiosurgery for primary and recurrent glioblastoma: Systematic review and meta-analysis with target- and protocol-based stratification"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-162X","authenticated-orcid":false,"given":"Pierfrancesco","family":"De Domenico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Roncelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Snider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina Raffaella","family":"Barzaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Mortini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"_4","key":"10.1016\/j.critrevonc.2025.104988_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104988_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104988_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104988_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"32","key":"10.1016\/j.critrevonc.2025.104988_bib5","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104988_bib6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0042-1749351","article-title":"Updates in the management of recurrent glioblastoma multiforme","volume":"84","author":"Prajapati","year":"2023","journal-title":"J. Neurol. Surg. A Cent. Eur. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104988_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.wneu.2018.04.016","article-title":"The survival effect of repeat surgery at glioblastoma recurrence and its trend: a systematic review and meta-analysis","volume":"115","author":"Lu","year":"2018","journal-title":"World Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104988_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2020.00151","article-title":"Gross total vs. subtotal resection on survival outcomes in elderly patients with high-grade glioma: a systematic review and meta-analysis","volume":"10","author":"Han","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11060-025-05156-0","article-title":"Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review","volume":"175","author":"Kite","year":"2025","journal-title":"J. Neurooncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104988_bib11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104988_bib12","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","article-title":"MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR Trial","volume":"21","author":"Weller","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104988_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251343574","article-title":"Efficacy and safety of combining re-irradiation with bevacizumab compared to bevacizumab alone in the management of recurrent high-grade gliomas: a meta-analysis and systematic review","volume":"18","author":"Hammed","year":"2025","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"34","key":"10.1016\/j.critrevonc.2025.104988_bib14","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1200\/JCO.2005.03.4157","article-title":"Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution","volume":"23","author":"Combs","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ijrobp.2017.06.2466","article-title":"Multicenter, phase 1, dose escalation study of hypofractionated stereotactic radiation therapy with bevacizumab for recurrent glioblastoma and anaplastic astrocytoma","volume":"99","author":"Clarke","year":"2017","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104988_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.critrevonc.2018.03.024","article-title":"Re-irradiation as salvage treatment in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions","volume":"126","author":"Scoccianti","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104988_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2407-5-55","article-title":"Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma","volume":"5","author":"Vordermark","year":"2005","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104988_bib18","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","article-title":"Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas","volume":"28","author":"Fogh","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.nec.2020.08.007","article-title":"Radiosurgery for glioblastoma","volume":"32","author":"Bunevicius","year":"2021","journal-title":"Neurosurg. Clin. N. Am."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104988_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radio. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/mp.14690","article-title":"A unified multi-activation (UMA) model of cell survival curves over the entire dose range for calculating equivalent doses in stereotactic body radiation therapy (SBRT), high dose rate brachytherapy (HDRB), and stereotactic radiosurgery (SRS)","volume":"48","author":"Li","year":"2021","journal-title":"Med. Phys."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/0118744710300495240409074900","article-title":"Hypofractionated radiation therapy suppresses radioresistance in U87 human glioma cells by inhibiting Yap1 and Hsp90 proteins","volume":"17","author":"Khan","year":"2024","journal-title":"Curr. Radio."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000448924","article-title":"Gamma knife radiosurgery in recurrent glioblastoma","volume":"94","author":"Frischer","year":"2016","journal-title":"Stereo Funct. Neurosurg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-011-0744-9","article-title":"Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study","volume":"107","author":"Park","year":"2012","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s10143-025-03632-9","article-title":"Efficacy of combined therapy with gamma knife radiosurgery and bevacizumab on survival outcomes in patients with recurrent high-grade glioma: a systematic review and meta-analysis","volume":"48","author":"Aghedi","year":"2025","journal-title":"Neurosurg. Rev."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104988_bib28","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ijrobp.2006.02.042","article-title":"A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023","volume":"65","author":"Cardinale","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104988_bib29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.canrad.2010.03.021","article-title":"[Systematic review of stereotactic radiotherapy for high-grade gliomas]","volume":"14","author":"Clavier","year":"2010","journal-title":"Cancer Radio."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.critrevonc.2025.104988_bib31","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104988_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.critrevonc.2025.104988_bib34","unstructured":"McGrath, S., et al., Meta-analysis of median survival times with inverse-variance weighting. arXiv.2503.03065, 2025."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/neuros\/nyx369","article-title":"Phase I trial of radiosurgery dose escalation plus bevacizumab in patients with recurrent\/progressive glioblastoma","volume":"83","author":"Abbassy","year":"2018","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3340\/jkns.2017.0259","article-title":"Efficacy of gamma knife radiosurgery for recurrent high-grade gliomas with limited tumor volume","volume":"61","author":"Cheon","year":"2018","journal-title":"J. Korean Neurosurg. Soc."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104988_bib37","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1016\/j.wneu.2014.06.011","article-title":"Increased survival using delayed gamma knife radiosurgery for recurrent high-grade glioma: a feasibility study","volume":"82","author":"Dodoo","year":"2014","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-020-03689-0","article-title":"Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma","volume":"152","author":"Dono","year":"2021","journal-title":"J. Neurooncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib39","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1093\/neuros\/nyy520","article-title":"Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years","volume":"85","author":"Ene","year":"2019","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib40","first-page":"281","article-title":"Gamma knife radiosurgery for local recurrence of glioblastoma","volume":"39","author":"Guseynova","year":"2018","journal-title":"Neuro Endocrinol. Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuchi.2024.101532","article-title":"Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy","volume":"70","author":"Hatiboglu","year":"2024","journal-title":"Neurochirurgie"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib42","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1227\/01.NEU.0000175550.96901.A3","article-title":"Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme","volume":"57","author":"Hsieh","year":"2005","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1227\/NEU.0000000000001344","article-title":"Indications and efficacy of gamma knife stereotactic radiosurgery for recurrent glioblastoma: 2 decades of institutional experience","volume":"80","author":"Imber","year":"2017","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jocn.2014.09.018","article-title":"Outcome of salvage treatment for recurrent glioblastoma","volume":"22","author":"Kim","year":"2015","journal-title":"J. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-006-9283-1","article-title":"Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas","volume":"82","author":"Kohshi","year":"2007","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-023-04398-0","article-title":"Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme","volume":"164","author":"Mantica","year":"2023","journal-title":"J. Neurooncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3171\/2018.4.JNS172909","article-title":"Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery","volume":"131","author":"Sharma","year":"2019","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib48","article-title":"PET-CT guided gamma knife radiosurgery for recurrent glioblastoma multiforme recurrent cases in Pakistan","volume":"27","author":"Shibli","year":"2023","journal-title":"Pak. J. Neurol. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104988_bib49","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.wneu.2012.03.024","article-title":"Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme","volume":"78","author":"Skeie","year":"2012","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-023-04524-y","article-title":"Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma","volume":"166","author":"Zhang","year":"2024","journal-title":"J. Neurooncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10143-015-0632-4","article-title":"Factors predictive of improved overall survival following stereotactic radiosurgery for recurrent glioblastoma","volume":"38","author":"Bir","year":"2015","journal-title":"Neurosurg. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3171\/2021.7.JNS211277","article-title":"Stereotactic radiosurgery for glioblastoma considering tumor genetic profiles: an international multicenter study","volume":"137","author":"Bunevicius","year":"2022","journal-title":"J. Neurosurg."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104988_bib53","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/B:NEON.0000021825.41221.b5","article-title":"Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma","volume":"67","author":"Landy","year":"2004","journal-title":"J. Neurooncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib54","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3171\/2014.11.JNS13295","article-title":"Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era","volume":"122","author":"Niranjan","year":"2015","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.critrevonc.2025.104988_bib55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3171\/JNS\/2008\/109\/12\/S17","volume":"109","author":"Smith","year":"2008","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib56","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3171\/2010.2.JNS091607","article-title":"Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation","volume":"113","author":"Tamura","year":"2010","journal-title":"J. Neurosurg."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104988_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14101049","article-title":"Efficacy and cognitive outcomes of gamma knife radiosurgery in glioblastoma management for elderly patients","volume":"14","author":"Valerio","year":"2024","journal-title":"J. Pers. Med."},{"issue":"ement","key":"10.1016\/j.critrevonc.2025.104988_bib58","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.4103\/0028-3886.373625","article-title":"Early gamma knife therapy (Without EBRT) in operated patients of glioblastoma multiforme","volume":"71","author":"Rai","year":"2023","journal-title":"Neurol. India"},{"key":"10.1016\/j.critrevonc.2025.104988_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3171\/sup.2006.105.7.139","article-title":"Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme","volume":"105","author":"Kong","year":"2006","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3171\/2016.7.GKS161460","article-title":"Upfront boost Gamma Knife \"leading-edge\" radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy","volume":"125","author":"Duma","year":"2016","journal-title":"J. Neurosurg."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib61","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijrobp.2012.01.020","article-title":"Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme","volume":"84","author":"Einstein","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib62","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1186\/s12885-022-10162-w","article-title":"Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma","volume":"22","author":"Gallitto","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib63","first-page":"41","article-title":"Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme","volume":"50","author":"Nwokedi","year":"2002","journal-title":"Neurosurgery"},{"key":"10.1016\/j.critrevonc.2025.104988_bib64","doi-asserted-by":"crossref","first-page":"247","DOI":"10.25259\/SNI_706_2020","article-title":"C-methionine-PET-guided Gamma Knife radiosurgery boost as adjuvant treatment for newly diagnosed glioblastomas","volume":"12","author":"Jacobo","year":"2021","journal-title":"Surg. Neurol. Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib65","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11060-021-03883-8","article-title":"Stereotactic radiosurgery for IDH wild type glioblastoma: an international, multicenter study","volume":"155","author":"Bunevicius","year":"2021","journal-title":"J. Neurooncol."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104988_bib66","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.wneu.2010.12.053","article-title":"Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection","volume":"76","author":"Elliott","year":"2011","journal-title":"World Neurosurg."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib67","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00006123-200002000-00011","article-title":"A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas","volume":"46","author":"Graves","year":"2000","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11060-017-2478-9","article-title":"MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma","volume":"133","author":"Kim","year":"2017","journal-title":"J. Neurooncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104988_bib69","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0360-3016(02)03743-4","article-title":"Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma","volume":"54","author":"Larson","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104988_bib70","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/j.wneu.2019.03.193","article-title":"Gamma knife stereotactic radiosurgery in combination with bevacizumab for recurrent glioblastoma","volume":"127","author":"Morris","year":"2019","journal-title":"World Neurosurg."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-9873-9","article-title":"Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma","volume":"94","author":"Pouratian","year":"2009","journal-title":"J. Neurooncol"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104988_bib72","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1002\/cncr.27372","article-title":"Extended field stereotactic radiosurgery for recurrent glioblastoma","volume":"118","author":"Koga","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00006123-199710000-00004","article-title":"Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms","volume":"41","author":"Kondziolka","year":"1997","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104988_bib74","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0360-3016(96)00427-0","article-title":"Gamma knife for glioma: selection factors and survival","volume":"36","author":"Larson","year":"1996","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib75","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12885-023-11772-8","article-title":"Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma","volume":"24","author":"Sun","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib76","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4103\/ATMR.ATMR_128_24","article-title":"Reirradiation with or without bevacizumab for recurrent or progressive high-grade gliomas: a systematic review and meta-analysis","volume":"1","author":"Aleid","year":"2024","journal-title":"J. Adv. Trends Med. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11060-023-04441-0","article-title":"Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity","volume":"164","author":"Marwah","year":"2023","journal-title":"J. Neurooncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104988_bib78","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00701-021-04794-3","article-title":"Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review","volume":"163","author":"Kulinich","year":"2021","journal-title":"Acta Neurochir."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12885-021-07856-y","article-title":"Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience","volume":"21","author":"Guan","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib80","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10143-024-02585-9","article-title":"Stereotactic radiosurgery versus combined stereotactic radiosurgery and bevacizumab for recurrent glioblastoma; a systematic review and meta-analysis of survival","volume":"47","author":"Habibi","year":"2024","journal-title":"Neurosurg. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104988_bib81","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: a randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104988_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111723","article-title":"Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis","volume":"11","author":"Kaka","year":"2019","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/neuonc\/nop027","article-title":"Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice","volume":"12","author":"de Groot","year":"2010","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib84","first-page":"144","article-title":"Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis","volume":"6","author":"Shanker","year":"2019","journal-title":"Neurooncol. Pr."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104988_bib85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11060-023-04340-4","article-title":"Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis","volume":"163","author":"Moore-Palhares","year":"2023","journal-title":"J. Neurooncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104988_bib86","article-title":"Stereotactic radiosurgery for recurrent glioblastoma multiforme: a retrospective multi-institutional experience","volume":"13","author":"Lovo","year":"2021","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104988_bib87","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/cncr.21429","article-title":"Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM)","volume":"104","author":"Combs","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104988_bib88","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818806498","article-title":"Hypofractionated stereotactic radiotherapy as a salvage therapy for recurrent high-grade gliomas: single-center experience","volume":"17","author":"Reynaud","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104988_bib89","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/neuonc\/noad074","article-title":"Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: a report of the RANO resect group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104988_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11060-013-1059-9","article-title":"Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?","volume":"112","author":"Shah","year":"2013","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.critrevonc.2025.104988_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111150","article-title":"Stereotactic radiosurgery for recurrent high-grade gliomas","volume":"135","author":"Kite","year":"2025","journal-title":"J. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104988_bib92","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/neuonc\/noae058","article-title":"NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma","volume":"26","author":"Sloan","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.critrevonc.2025.104988_bib93","doi-asserted-by":"crossref","first-page":"1274587","DOI":"10.3389\/fonc.2023.1274587","article-title":"Enhancing glioblastoma treatment through the integration of tumor-treating fields","volume":"13","author":"Szklener","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104988_bib94","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s12672-025-03285-6","article-title":"Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104988_bib95","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tips.2015.02.002","article-title":"Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones","volume":"36","author":"Sehedic","year":"2015","journal-title":"Trends Pharm. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104988_bib96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/cco-22-90","article-title":"Tumor treating fields with radiation for glioblastoma: a narrative review","volume":"11","author":"Miller","year":"2022","journal-title":"Chin. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:14:37Z","timestamp":1767388477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":96,"alternative-id":["S1040842825003762"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104988","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gamma Knife radiosurgery for primary and recurrent glioblastoma: Systematic review and meta-analysis with target- and protocol-based stratification","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104988"}}